Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)
1.600
-0.070 (-4.19%)
Apr 17, 2025, 2:18 PM HKT
HKG:8049 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Revenue | 881.16 | 841.55 | 841.59 | 705.46 | 622.25 | Upgrade
|
Revenue Growth (YoY) | 4.71% | -0.01% | 19.30% | 13.37% | -3.66% | Upgrade
|
Cost of Revenue | 195.91 | 257.5 | 193.55 | 126.19 | 90.54 | Upgrade
|
Gross Profit | 685.25 | 584.05 | 648.04 | 579.27 | 531.71 | Upgrade
|
Selling, General & Admin | 522.19 | 448.95 | 509.95 | 453.27 | 428.35 | Upgrade
|
Other Operating Expenses | -21.57 | -25.55 | -19.91 | -14.63 | -11.07 | Upgrade
|
Operating Expenses | 500.62 | 423.41 | 490.04 | 438.64 | 417.28 | Upgrade
|
Operating Income | 184.63 | 160.64 | 158 | 140.63 | 114.43 | Upgrade
|
Interest Expense | -2.03 | -0.52 | -0.48 | -0.34 | -0.71 | Upgrade
|
Interest & Investment Income | 18.76 | 33.12 | 35.31 | 33.59 | 28.19 | Upgrade
|
EBT Excluding Unusual Items | 201.37 | 193.24 | 192.83 | 173.87 | 141.9 | Upgrade
|
Gain (Loss) on Sale of Investments | 5.34 | 5.43 | 4.52 | 3.4 | 8.14 | Upgrade
|
Asset Writedown | 0.46 | -0.36 | - | - | - | Upgrade
|
Pretax Income | 207.16 | 198.31 | 197.35 | 177.27 | 150.04 | Upgrade
|
Income Tax Expense | 22.91 | 50.11 | 3.78 | 33.99 | 23.48 | Upgrade
|
Net Income | 184.25 | 148.21 | 193.57 | 143.28 | 126.56 | Upgrade
|
Net Income to Common | 184.25 | 148.21 | 193.57 | 143.28 | 126.56 | Upgrade
|
Net Income Growth | 24.32% | -23.43% | 35.09% | 13.21% | -12.55% | Upgrade
|
Shares Outstanding (Basic) | 560 | 560 | 560 | 560 | 560 | Upgrade
|
Shares Outstanding (Diluted) | 560 | 560 | 560 | 560 | 560 | Upgrade
|
EPS (Basic) | 0.33 | 0.26 | 0.35 | 0.26 | 0.23 | Upgrade
|
EPS (Diluted) | 0.33 | 0.26 | 0.35 | 0.26 | 0.23 | Upgrade
|
EPS Growth | 24.32% | -23.43% | 35.09% | 13.21% | -12.55% | Upgrade
|
Free Cash Flow | 208.63 | 284.11 | 192.68 | 122.26 | 52.46 | Upgrade
|
Free Cash Flow Per Share | 0.37 | 0.51 | 0.34 | 0.22 | 0.09 | Upgrade
|
Gross Margin | 77.77% | 69.40% | 77.00% | 82.11% | 85.45% | Upgrade
|
Operating Margin | 20.95% | 19.09% | 18.77% | 19.93% | 18.39% | Upgrade
|
Profit Margin | 20.91% | 17.61% | 23.00% | 20.31% | 20.34% | Upgrade
|
Free Cash Flow Margin | 23.68% | 33.76% | 22.89% | 17.33% | 8.43% | Upgrade
|
EBITDA | 210.65 | 187.09 | 190.43 | 168.72 | 135.66 | Upgrade
|
EBITDA Margin | 23.91% | 22.23% | 22.63% | 23.92% | 21.80% | Upgrade
|
D&A For EBITDA | 26.02 | 26.45 | 32.43 | 28.09 | 21.23 | Upgrade
|
EBIT | 184.63 | 160.64 | 158 | 140.63 | 114.43 | Upgrade
|
EBIT Margin | 20.95% | 19.09% | 18.77% | 19.93% | 18.39% | Upgrade
|
Effective Tax Rate | 11.06% | 25.27% | 1.92% | 19.17% | 15.65% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.